MaxCyte Statistics
Total Valuation
MaxCyte has a market cap or net worth of $73.05 million. The enterprise value is -$12.05 million.
Important Dates
The last earnings date was Tuesday, March 24, 2026, after market close.
| Earnings Date | Mar 24, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MaxCyte has 106.86 million shares outstanding. The number of shares has increased by 1.51% in one year.
| Current Share Class | 106.86M |
| Shares Outstanding | 106.86M |
| Shares Change (YoY) | +1.51% |
| Shares Change (QoQ) | +0.11% |
| Owned by Insiders (%) | 1.06% |
| Owned by Institutions (%) | 74.48% |
| Float | 105.73M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.21 |
| Forward PS | 1.84 |
| PB Ratio | 0.43 |
| P/TBV Ratio | 0.43 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.30, with a Debt / Equity ratio of 0.10.
| Current Ratio | 8.30 |
| Quick Ratio | 7.47 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -23.63% and return on invested capital (ROIC) is -13.46%.
| Return on Equity (ROE) | -23.63% |
| Return on Assets (ROA) | -12.60% |
| Return on Invested Capital (ROIC) | -13.46% |
| Return on Capital Employed (ROCE) | -23.66% |
| Weighted Average Cost of Capital (WACC) | 9.72% |
| Revenue Per Employee | $362,923 |
| Profits Per Employee | -$490,440 |
| Employee Count | 91 |
| Asset Turnover | 0.15 |
| Inventory Turnover | 0.76 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -75.41% in the last 52 weeks. The beta is 1.43, so MaxCyte's price volatility has been higher than the market average.
| Beta (5Y) | 1.43 |
| 52-Week Price Change | -75.41% |
| 50-Day Moving Average | 0.85 |
| 200-Day Moving Average | 1.49 |
| Relative Strength Index (RSI) | 34.93 |
| Average Volume (20 Days) | 1,040,774 |
Short Selling Information
The latest short interest is 5.49 million, so 5.14% of the outstanding shares have been sold short.
| Short Interest | 5.49M |
| Short Previous Month | 5.75M |
| Short % of Shares Out | 5.14% |
| Short % of Float | 5.19% |
| Short Ratio (days to cover) | 4.68 |
Income Statement
In the last 12 months, MaxCyte had revenue of $33.03 million and -$44.63 million in losses. Loss per share was -$0.42.
| Revenue | 33.03M |
| Gross Profit | 26.80M |
| Operating Income | -44.53M |
| Pretax Income | -44.63M |
| Net Income | -44.63M |
| EBITDA | -40.22M |
| EBIT | -44.53M |
| Loss Per Share | -$0.42 |
Full Income StatementBalance Sheet
The company has $103.04 million in cash and $17.94 million in debt, with a net cash position of $85.10 million or $0.80 per share.
| Cash & Cash Equivalents | 103.04M |
| Total Debt | 17.94M |
| Net Cash | 85.10M |
| Net Cash Per Share | $0.80 |
| Equity (Book Value) | 171.49M |
| Book Value Per Share | 1.61 |
| Working Capital | 104.10M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$34.41 million and capital expenditures -$1.77 million, giving a free cash flow of -$36.18 million.
| Operating Cash Flow | -34.41M |
| Capital Expenditures | -1.77M |
| Depreciation & Amortization | 4.31M |
| Net Borrowing | n/a |
| Free Cash Flow | -36.18M |
| FCF Per Share | -$0.34 |
Full Cash Flow StatementMargins
Gross margin is 81.16%, with operating and profit margins of -134.85% and -135.14%.
| Gross Margin | 81.16% |
| Operating Margin | -134.85% |
| Pretax Margin | -135.14% |
| Profit Margin | -135.14% |
| EBITDA Margin | -121.79% |
| EBIT Margin | -134.85% |
| FCF Margin | n/a |
Dividends & Yields
MaxCyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.51% |
| Shareholder Yield | -1.51% |
| Earnings Yield | -61.09% |
| FCF Yield | -49.52% |
Analyst Forecast
The average price target for MaxCyte is $5.50, which is 704.56% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.50 |
| Price Target Difference | 704.56% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 34.73% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MaxCyte has an Altman Z-Score of 3.18 and a Piotroski F-Score of 1.
| Altman Z-Score | 3.18 |
| Piotroski F-Score | 1 |
